Last checked at 5 Oct 2012 14:59
For immediate release | 5 October 2012 |
Futura Medical plc
("Futura" or "the Company")
Director's Dealings
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has received notification from James Barder, the Chief Executive of the Company, that he and his wife have today gifted in aggregate 50,000 ordinary shares in the Company to a shareholding account jointly held by their children. Although no disposal has taken place for the purposes of the AIM Rules for Companies, Mr Barder's revised aggregate beneficial holding and non-beneficial holdings will now be 925,330 ordinary shares.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
| Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com